AzTrials
AzTrials

Diabetes Type 1EPICAM-G6NCT07048795

Impact of the Mylife CamAPS FX System With the DEXCOM G6 Sensor on T1D Patients in France

An observational study of Diabetes Type 1, run by mylife Diabetes Care AG at 22 sites in France.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

This is a non-interventional, longitudinal, prospective, multicenter, post market-registration and national study conducted in France. The study is conducted among participants with type 1 diabetes (T1D) using the mylife CamAPS FX hybrid closed-loop insulin delivery system combined with the DEXCOM G6 Continuous… Read more about this study

Who is it for?
Any age
Conditions the study is for
Diabetes Type 1
How many people
125 participants
Where
22 sitesFrance
Study dates
11 Dec 2025to Dec 2027
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages Any age
  • All sexes
  • No healthy volunteers
  • Child, Adult, Older adult

Study population: The study population will be recruited from 22 French participating centers, which are defined as insulin pump initiation hospital centers according to the definition of the Francophone Diabetic Society.

Who may be able to join

  • Patients with type 1 diabetes who have been using a Dexcom or Abbott Libre glucose sensor (any model) for at least 14 days prior to the date of installation of the mylife YpsoPump, with at least 70% coverage, under the same sensor.
  • Patient for whom the diabetes specialist decides to initiate the mylife CamAPS FX hybrid closed loop.
  • Patient who received the information sheets and gave their consent to participate in the study and to the processing of their personal data.
  • Adult patient who signed an informed consent form to participate in the study or minor patient whose parents signed an informed consent form for their child's participation in the study.
  • Adult patient, minor patient old enough to complete the questionnaires or parent of a minor patient able to read and understand French.
  • Adult patient / minor patient capable to complete the questionnaires or parent of a minor patient who agrees to complete the online self-questionnaires.

Who cannot join

  • Patient who used a hybrid closed-loop system, a fully closed-loop system, or a do-it-yourself loop system, regardless of the brand or model, within the past 6 months.
  • Patients participating or having participated in a clinical trial in the previous month that prevents them from participating in other studies.
  • Patient or parent unable to give consent.
  • Protected Patient (subject to a legal protection measure: guardianship, curatorship or legal safeguard).
  • Patient with a contraindication to the prescription of the mylife CamAPS FX hybrid closed-loop ( according to the Instructions For Use, IFU).
  • Patient with an unresolved skin condition in the area of sensor placement and/or in the tubing placement area (e.g. psoriasis, dermatitis herpetiformis, rash, staphylococcal infection).
Show all 9Show fewer
  • Patient with unstable diabetic retinopathy requiring laser treatment.
  • Patient with a concomitant condition or treatment that alters glucose metabolism and that, in the investigator's judgment, is likely to have a significant impact on glycemic control;
  • Patient whose follow-up cannot be carried out by the centre (relocation planned within 12 months of inclusion).

Trial locations and contacts

22 sites in 1 country. Contact the study team or a site near you to ask about taking part.

22 sites in 1 country

France22 sites, 22 recruiting
  • CHU Amiens

    Amiens, 80054

    Recruiting
  • Hôtel Dieu-Pédiatrie

    Angers, 49933

    Recruiting
  • CH Victor Dupouy

    Argenteuil, 95107

    Recruiting
  • Hôpital Bois Guillaume

    Bois-Guillaume, 76230

    Recruiting
  • CHU de Bordeaux

    Bordeaux, 33000

    Recruiting
  • CHU Brest - Hôpital La Cavale Blanche

    Brest, 29609

    Recruiting
  • Hôpital Femme Mère Enfant Lyon

    Bron, 69677

    Recruiting
  • CHU Grenoble Alpes

    Grenoble, 38042

    Recruiting
  • Groupe Hospitalier de la Rochelle Ré Aunis

    La Rochelle, 17019

    Recruiting
  • Hospices Civils de Lyon DIAB-Ecare

    Lyon, 69008

    Recruiting
  • Hôpital Européen

    Marseille, 13003

    Recruiting
  • Hôpital Europeen Georges Pompidou

    Paris, 75015

    Recruiting
  • Hôpital Universitaire Necker Enfants Malades

    Paris, 75015

    Recruiting
  • Groupe hospitalier Bichat Claude Bernard

    Paris, 75018

    Recruiting
  • CH Périgueux

    Périgueux, 24000

    Recruiting
  • CHU Poitiers

    Poitiers, 86021

    Recruiting
  • Hôpital NOVO, Site Pontoise

    Pontoise, 95300

    Recruiting
  • CHU Toulouse

    Toulouse, 31059

    Recruiting
  • Clinique Pasteur

    Toulouse, 31300

    Recruiting
  • CHRU Nancy-Hôpitaux de Brabois Adultes

    Vandœuvre-lès-Nancy, 54511

    Recruiting
  • CH Bretagne Atlantique

    Vannes, 56017

    Recruiting
  • Hôpital Robert Schuman-UNEOS

    Vantoux, 57070

    Recruiting

Other trials in France

About this study

Official title: Impact de l'Utilisation du système Mylife CamAPS FX associé au Capteur DEXCOM G6 Sur le contrôle glycémique et la qualité de Vie de Patients DT1, en Vie réelle, en France

This is a non-interventional, longitudinal, prospective, multicenter, post market-registration and national study conducted in France. The study is conducted among participants with type 1 diabetes (T1D) using the mylife CamAPS FX hybrid closed-loop insulin delivery system combined with the DEXCOM G6 Continuous Glucose Monitoring (CGM) sensor (the System).

The main objective of the study is to evaluate, under real-life conditions, the impact of the System on glycemic control in participants with T1D after one year of use.

Read more

Secondary objectives include assessing participant-reported outcomes, such as quality-of-life, treatment satisfaction, fear of hypoglycemia, and sleep quality, describing complications related to the system, the rate of hybrid closed-loop usage over one year, and analyzing system usage parameters.

The study will involve approximately 125 participants (including 100 adults and 25 minors) across 22 centers in France. Patients will be followed up for 12 months.

Read the detailed description

This study, called EPICAM-PMCF-G6, is part of a Post-Market Clinical Follow-up (PMCF) requested by the French Health Technology Assessment Committee (CNEDiMTS), following the listing of the System for reimbursement under the national healthcare system in France.

Conditions
Diabetes Type 1
Being tested
No Intervention: Observational Cohort
Keywords
Diabetes Mellitus, Type 1, Real-life use, mylife CamAPS FX, YpsoPump, Hybrid closed loop
Medical subject headings
Diabetes Mellitus, Type 1

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • No Intervention: Observational CohortOther

    No intervention

Study groups in NCT07048795
Study groupRoleWhat they receive
Participants with type 1 diabetes initiating the hybrid closed-loop systemParticipants (adults and minors) with type 1 diabetes (T1D) initiating the mylife CamAPS FX system combined with the Dexcom G6 sensor, under real-life management conditions
Receives: Other: No Intervention: Observational Cohort

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change in Time in Range (TIR)

    Change in Time in Range (TIR, 70-180 mg/dL; for pregnant women: TIR, 63-140 mg/dL) (%)

    Measured: Baseline and 3 months

Secondary outcomes (17)
  1. Change in Time in Range (TIR)

    Change in Time in Range (TIR, 70-180 mg/dL; for pregnant women: TIR, 63-140 mg/dL) (%)

    Measured: Baseline and 12 months

  2. Change in Time In Tight Range (TITR)

    Change in Time In Tight Range (TITR, 70 - 140 mg/dL) (%)

    Measured: Baseline, 3 and 12 months

  3. Change in Time Above Range (TAR)

    Change in Time Above Range (TAR, > 250 mg/dL and > 180 mg/dL; for pregnant women: TAR, > 140 mg/dL) (%)

    Measured: Baseline, 3 months, and 12 months

  4. Change in Time Below Range (TBR)

    Change in Time Below Range (TBR, < 70 mg/dL and < 54 mg/dL; for pregnant women: TBR, < 63 mg/dL and < 54 mg/dL) (%)

    Measured: Baseline, 3 and 12 months

  5. Change in average glucose levels from CGM sensor data

    Change in average glucose levels from CGM sensor data (mg/dL)

    Measured: Baseline, 3 months and 12 months

  6. Change in Standard Deviation (SD) of glucose

    Change in Standard Deviation (SD) of glucose

    Measured: Baseline, 3 months and 12 months

  7. Change in Coefficient of Variation (CV) of glucose

    Change in Coefficient of Variation (CV) of glucose derived from CGM sensor data (%)

    Measured: Baseline, 3 months and 12 months

  8. Change in Glucose Management Indicator (GMI)

    Change in Glucose Management Indicator (GMI) (%) derived from CGM sensor data

    Measured: Baseline, 3 months and 12 months

  9. Change in HbA1c

    Change in HbA1c (%)

    Measured: Baseline, 3 months and 12 months

  10. Time in hybrid closed-loop

    Time spent in hybrid closed-loop (%)

    Measured: 3 months and 12 months

  11. System usage modalities

    Description of evolution rate of advanced features

    Measured: 3 months and 12 months

  12. Change in the PAID questionnaire score

    Self-administered questionnaire: Problem Areas In Diabetes (PAID)

    Following versions will be used: Adult version (18 and above), Teen version (PAID-T) in adolescents aged 12-18 years, and for their parents (P-PAID-T), Children version (PAID-C) in children aged 8-11 years and their parents (P-PAID-C). P-PAID-C will be also used in parents of children aged <8 years.

    The Problem Areas in Diabetes (PAID) questionnaire assesses diabetes-related emotional distress across patients and caregivers using age- and role-specific versions. The PAID (adults), PAID-T (teens), and PAID-C (children) are self-reported, while P-PAID-T and P-PAID-C are completed by parents of teens and children, respectively. All versions use Likert scales and are typically transformed to a 0-100 score, with higher values indicating greater distress.

    Measured: Baseline, 3 months and 12 months

  13. Change in the DTSQ questionnaire score

    Self-administered questionnaire: Diabetes Treatment Satisfaction Questionnaire (DTSQs)

    Following versions will be used: Adult version (18 and above), Teen version (DTSQs-Teen) in adolescents aged 13-18 years. For their parents and parents of children aged <13 years, Parent version (DTSQs-Parent) will be used.

    DTSQQs for adults contains 8 items, DTSQs-Teen has 12 items and DTSQs-Parent has 14 items. The total score of the DTSQs is calculated by summing six items (excluding perceived hypo/hyperglycaemia), each rated 0 to 6, resulting in a total score from 0 to 36, with higher scores indicating better treatment satisfaction.

    Measured: Baseline, 3 months and 12 months

  14. Change in the HFS-II questionnaire score

    Self-administered questionnaire Hypoglycemia Fear Survey II (HFS-II).

    The following versions will be used: Adult version, Children version (HFS-II children) for children aged 6 years and above, Parent version (HFS-II parent) for children aged 8 years and above, and Parent version for children aged <8 years (HFS-II parent of young children).

    HFS-II consists of items ranging from 0 (never) to 4 (almost always) (9 items in the Adult version, 25 in the Teen version and 26 in the Parent versions). It is composed of two subscales: a Behavior score and a Worry score, with higher scores reflecting greater behavioral or emotional impact.

    Measured: Baseline, 3 months and 12 months

  15. Change in the PSQI questionnaire score

    Self-administered questionnaire: Pittsburgh Sleep Quality Index (PSQI).

    The questionnaire will be used in adults and parents. It contains 19 items which are grouped into 7 components that contribute to the overall score. Each component is scored from 0 to 3, where 0 indicates no difficulty and 3 indicates severe difficulty. The 7 component scores are summed to produce a total score ranging from 0 to 21.

    Measured: Baseline, 3 months and 12 months

  16. Perceived changes in quality of life, treatment satisfaction, fear of hypoglycemia, and sleep quality

    Participant reported perceived changes in quality of life, treatment satisfaction, fear of hypoglycemia and sleep quality measured with a question " Patient Global Impression of Change " (PGIC) (one for each dimension).

    Each PGIC will be used in adults, parents and children aged 11 years and above and consisting of one question with 7 modalities from 'Much worse" to "Much better".

    Measured: Baseline, at 3 months and 12 months

  17. Safety / Adverse events related to the use of the System

    Number of diabetic ketoacidosis events, severe hypoglycemia requiring assistance (medical and non-medical), unplanned hospitalizations related to diabetes and other complications related to the use of the system that meet the predefined acceptance criteria based on safety parameters for the target devices.

    Measured: 3 months and 12 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted2 Jul 2025
  2. Study start11 Dec 2025
  3. Primary completionMar 2027 (estimated)
  4. Study completionDec 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
125 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07048795
Sponsor's protocol ID
2024-A00207-40
Acronym
EPICAM-G6
Status last verified
Jul 2026
First submitted
24 Jun 2025
Last updated
9 Jul 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No: In accordance with the General Data Protection Regulation and French data protection laws the presentation of the results derived from data processing shall under no circumstances allow the direct or indirect identification of individuals participating in the study. In the event of publication of the study findings in a scientific journal, access to the data by an independent expert - including one appointed by a scientific publisher - shall only be granted through the interface provided or designated by the Data Controller, solely for the purpose of verifying or reproducing the analyses, and exclusively under the conditions defined for secure consultation and data handling. The study is a non-interventional trial.

Questions about this trial

What is this clinical trial studying?

An observational study of Diabetes Type 1, run by mylife Diabetes Care AG at 22 sites in France.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 9 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 22 sites in France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Ingo Braun, Dr. (+41582347132, clinical-studies@mylife-diabetescare.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change in Time in Range (TIR) (time frame: Baseline and 3 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Jul 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in